AstraZeneca PLC (AZN) Financial Statements
AstraZeneca PLC (AZN) reported trailing twelve-month revenue of $61.4B (up 8.6% year on year) and net income of $10.5B as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: $11.8B.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
AZNAstraZeneca PLCFollow AZN — free
—
Price chart with a free account
- Market cap
- 274.1B
- P/E TTM
- 25.7
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 30 Oct, in 6 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22.47 | 22.09 | 24.38 | 26.62 | 37.42 | 44.35 | 45.81 | 54.07 | 58.74 | 61.37 | |
| Gross profit | — | — | — | — | — | — | 37.54 | 43.87 | 48.11 | 50.25 | |
| Research & development | — | — | — | — | — | — | 10.94 | 13.58 | 14.23 | — | |
| Operating income | 3.68 | 3.39 | 2.92 | 5.16 | 1.06 | 3.76 | 8.19 | 10.00 | 13.74 | 13.97 | |
| Pre-tax income | 2.23 | 1.99 | 1.55 | 3.92 | -0.27 | 2.50 | 6.90 | 8.69 | 12.40 | 12.59 | |
| Income tax | -0.64 | -0.06 | 0.32 | 0.77 | -0.38 | -0.79 | 0.94 | 1.65 | 2.17 | 2.13 | |
| Net income | 2.87 | 2.05 | 1.23 | 3.14 | 0.12 | 3.29 | 5.96 | 7.04 | 10.23 | 10.45 | |
| Diluted EPS ($) | 2.37 | 1.70 | 1.03 | 2.44 | 0.08 | 2.11 | 3.81 | 4.50 | 6.54 | 6.68 | |
| Diluted shares (bn) | 1.267 | 1.267 | 1.301 | 1.313 | 1.427 | 1.560 | 1.562 | 1.563 | 1.562 | — |
USD billions · SEC XBRL
AstraZeneca PLC — questions
- What is AstraZeneca PLC's revenue?
- $61.4B over the twelve months to 2026-06-30, up 8.6% year on year, from its 10-Q and 10-K filings.
- What is AstraZeneca PLC's net income?
- $10.5B over the twelve months to 2026-06-30.
- What is AstraZeneca PLC's free cash flow?
- $11.8B over the twelve months to 2026-06-30.
- What are AstraZeneca PLC's diluted earnings per share?
- $6.68 over the twelve months to 2026-06-30.
Every figure on this page comes from AstraZeneca PLC's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.